## IN THE CLAIMS

**Please cancel claims 4, 7, 11, 13-14, and 17-23 without prejudice or disclaimer.**

**Please add the following new claims 24-27.**

**This listing of the claims replaces all prior versions of the claims in the application.**

1. (Currently amended) An isolated polypeptide ~~comprising~~ selected from the group consisting of:

a) a[[n]] polypeptide comprising the amino acid sequence ~~selected from the group consisting~~ of SEQ ID NO:19, ~~SEQ ID NO:1, SEQ ID NO:3-5, SEQ ID NO:7-14, SEQ ID NO:16-31, SEQ ID NO:33-34, SEQ ID NO:36-40,SEQ ID NO:42-48, SEQ ID NO:50-55.~~

b) a polypeptide comprising a naturally occurring amino acid sequence having at least 90% sequence identity to [[an]] the amino acid sequence ~~selected from the group consisting~~ of SEQ ID NO:19, ~~SEQ ID NO:1, SEQ ID NO:3-5, SEQ ID NO:7-14, SEQ ID NO:16-31, SEQ ID NO:33-34, SEQ ID NO:36-40,SEQ ID NO:42-48, SEQ ID NO:50-55,~~

c) a biologically active fragment of a polypeptide comprising [[an]] the amino acid sequence ~~selected from the group consisting~~ of SEQ ID NO:19, and ~~SEQ ID NO:1, SEQ ID NO:3-5, SEQ ID NO:7-14, SEQ ID NO:16-31, SEQ ID NO:33-34, SEQ ID NO:36-40,SEQ ID NO:42-48, SEQ ID NO:50-55, or~~

d) an immunogenic fragment of [[an]] the amino acid sequence ~~selected from the group consisting~~ of SEQ ID NO:19. ~~SEQ ID NO:1, SEQ ID NO:3-5, SEQ ID NO:7-14, SEQ ID NO:16-31, SEQ ID NO:33-34, SEQ ID NO:36-40,SEQ ID NO:42-48, SEQ ID NO:50-55.~~

2. (Currently amended) An isolated polypeptide of claim 1, having [[an]] the amino acid sequence ~~selected from the group consisting~~ of SEQ ID NO:19. ~~SEQ ID NO:1, SEQ ID NO:3-5, SEQ ID NO:7-14, SEQ ID NO:16-31, SEQ ID NO:33-34, SEQ ID NO:36-40,SEQ ID NO:42-48, SEQ ID NO:50-55.~~

3. (Original) An isolated polynucleotide encoding a polypeptide of claim 1.

4. (Canceled).

5. (Original) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

6. (Original) A cell transformed with a recombinant polynucleotide of claim 5.

7. (Canceled).

8. (Original) A method for producing a polypeptide of claim 1, the method comprising:

a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

b) recovering the polypeptide so expressed.

9. (Original) An isolated antibody which specifically binds to a polypeptide of claim 1.

10. (Currently amended) An isolated polynucleotide ~~comprising~~ selected from the group consisting of:

a) a polynucleotide comprising the polynucleotide sequence ~~selected from the group consisting~~ of ~~SEQ ID NO:56-110~~ SEQ ID NO:74,

b) a polynucleotide comprising a naturally occurring polynucleotide sequence having at least 90% sequence identity to [[a]] the polynucleotide sequence ~~selected from the group consisting~~ of ~~SEQ ID NO:56-110~~ SEQ ID NO:74,

c) a polynucleotide ~~sequence~~ complementary to a), or

d) a polynucleotide ~~sequence~~ complementary to b)[[.]] , and

e) an RNA equivalent of a)-d).

11. (Canceled).

12. (Original) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 10, the method comprising:

a) hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

13.-14. (Canceled).

15. (Original) A pharmaceutical composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

16. (Original) A method of treating a disease or condition associated with decreased expression of functional NuABP, comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 15.

17.-23. (Canceled).

24. (New) A microarray wherein at least one element of the microarray is a polynucleotide of claim 3.

25. (New) A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:

a) labeling the polynucleotides of the sample,

b) contacting the elements of the microarray of claim 24 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and

c) quantifying the expression of the polynucleotides in the sample.

26. (New) An isolated polynucleotide consisting of at least 60 contiguous nucleotides of a polynucleotide of claim 10.

27. (New) A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 3, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,

b) detecting altered expression of the target polynucleotide, and

c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.